表紙:がんバイオマーカーの世界市場の評価:タイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)
市場調査レポート
商品コード
1417604

がんバイオマーカーの世界市場の評価:タイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)

Cancer Biomarkers Market Assessment, By Type, By Technology, By Cancer Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 224 Pages | 納期: 3~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
がんバイオマーカーの世界市場の評価:タイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)
出版日: 2024年01月29日
発行: Market Xcel - Markets and Data
ページ情報: 英文 224 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんバイオマーカーの市場規模は、2023年に151億米ドル、2031年に435億3,000万米ドルに達し、2024年~2031年の予測期間にCAGRで14.15%の成長が見込まれています。世界のがんバイオマーカー市場は、がんバイオマーカー周辺の研究環境の発達により成長が見込まれています。がんバイオマーカーは精密診断を提供することからがん検出の非常に効果的な方法であり、さまざまな市場企業がより効果的で正確ながんバイオマーカーを見つけるために研究を進めています。

遺伝子変異、ライフスタイルの変化、喫煙、飲酒などの要因により、がん患者数は近年大幅に増加しています。がん患者の増加は、より正確で迅速なスクリーニング方法を要求しており、市場成長を促進しています。がん患者の有病率の増加や最先端技術が、市場成長を促進すると予測されます。がん患者の増加、政府の取り組み、規制政策、技術の進歩などの要因が市場成長を促進すると予測されます。

2023年7月、診断情報サービスの主要プロバイダーであるQuest Diagnosticsは、Envision Sciencesと共同で、病理学を下位専門分野とする企業であるAmeriPathを通じて新規の前立腺がんバイオマーカー検査を開始すると発表しました。この新しい組織ベースの検査サービスは、男性における潜在的に攻撃的な前立腺がんの症例を同定し鑑別する検査に対する差し迫った臨床ニーズに対応することを目的としています。このような最先端の製品承認は、世界のがんバイオマーカー市場を牽引する重要な役割を果たすと予測されています。

がんバイオマーカーの研究開発の増加

がんは、先進国でも発展途上国でも例外なく、世界的に主要な死因の1つです。がんバイオマーカーはがんスクリーニングに大きく寄与しています。研究機関や市場参入企業は、政府当局、投資家、規制機関の支援を受けて、がんバイオマーカー研究に一貫して取り組んでいます。研究は主に、がんの診断、研究、治療を促進するためのさまざまなバイオマーカーの同定、最適化、活用に焦点を当てています。そのため、政府による研究開発への投資の増加や、がんバイオマーカー分野で活動する企業により、市場成長が促進されると予測されます。

2023年4月、フロリダ州立大学の化学者が率いるチームは、数種類のがんに関連する生物学的マーカーを検出する新しい検査を開発しました。この検出プラットフォームは、金ナノ粒子と色素で標識されたペプチドと呼ばれる分子でできています。金ナノ粒子は紫外線の存在下で色素が光るのを抑えます。酵素MMP-14(がんバイオマーカー)を含む患者サンプルをサンプル調製に加えると、ペプチド結合が切断され、色素を持つ断片が金から分離します。色素からのエネルギーを吸収する金がなければ、サンプルは光り始め、がんの存在が検出されます。

タンパク質バイオマーカーへの注目の高まり

タンパク質バイオマーカーは、がんスクリーニングに向け、患者だけでなく医療従事者からも注目を集めています。がん予測因子としてのタンパク質バイオマーカーの信頼性は、それががん患者で一貫して発現している場合に大きな意味を持っています。さらに、タンパク質バイオマーカーが広く発現していれば、バイオマーカーとしての同定が容易になります。質数量分析ベースのプロテオミクスツールは、がんバイオマーカーの同定に利用されています。がんスクリーニングに向けたタンパク質バイオマーカーへの注目の高まりは、タンパク質バイオマーカーに基づくがんスクリーニングの市場需要を増加させると予測されます。

2023年6月、デンマークのバイオマーカー企業Nordic Bioscienceは、同社のPRO-C3バイオマーカーアッセイがFDAからLoS(Letter of Support)を取得したと発表しました。PRO C3は、進行性の固形腫瘍患者を対象とした、タンパク質バイオマーカーに基づく世界初の血液ベースの腫瘍線維化バイオマーカーです。世界のがんバイオマーカー市場における有望な製品の規制当局による承認は、今後数年間の市場成長に寄与すると予測されます。

当レポートでは、世界のがんバイオマーカー市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界のがんバイオマーカー市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界のがんバイオマーカー市場の見通し(2017年~2031年)

  • 市場規模と予測
    • 金額
    • 数量
  • タイプ別
    • タンパク質バイオマーカー
    • 遺伝的バイオマーカー
    • その他のがんバイオマーカー
  • 技術別
    • オミックス
    • イメージング技術
    • イムノアッセイ
    • バイオインフォマティクス
    • 細胞遺伝学
  • がんタイプ別
    • 乳がん
    • 肺がん
    • 大腸がん
    • 黒色腫
    • 血液がん
    • 前立腺がん
    • 卵巣がん
    • 胃がん
    • 肝臓がん
    • その他のがん
  • 用途別
    • 診断
    • 研究開発
    • 予後
    • リスク評価
    • 治療
    • その他の用途
  • エンドユーザー別
    • 製薬企業、バイオテクノロジー企業
    • 診断研究所
    • がん研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア:企業別(2023年)

第6章 世界のがんバイオマーカー市場の見通し(2017年~2031年)

  • 北米
    • 市場規模と予測
    • タイプ別
    • 技術別
    • がんタイプ別
    • 用途別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第7章 市場マッピング(2023年)

  • タイプ別
  • 技術別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第8章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析 - 数量と金額
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第9章 市場力学

  • 成長促進要因
  • 成長抑制要因(課題、抑制要因)

第10章 規制枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第11章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析(2023年)
  • 合併と買収/合弁事業(該当する場合)
  • SWOT分析(市場参入企業5社)
  • 特許分析(該当する場合)

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

  • Abbott
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Merck KGaA
  • Hologic, Inc.
  • Bio-Rad Laboratories

第15章 戦略的推奨事項

第16章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 6. Global Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Cancer Biomarkers Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 11. North America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 12. North America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 14. North America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 19. United States Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 20. United States Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 21. United States Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. United States Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 26. Canada Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 27. Canada Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 28. Canada Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 29. Canada Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 33. Mexico Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 34. Mexico Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 35. Mexico Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 36. Mexico Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 40. Europe Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 41. Europe Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 42. Europe Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. Europe Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. Germany Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 49. Germany Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 50. Germany Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 51. Germany Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 55. France Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 56. France Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 57. France Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. France Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 59. France Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 62. Italy Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 63. Italy Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 64. Italy Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 65. Italy Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 69. United Kingdom Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 70. United Kingdom Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 71. United Kingdom Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 72. United Kingdom Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 76. Russia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 77. Russia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 78. Russia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 79. Russia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 83. Netherlands Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 84. Netherlands Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 85. Netherlands Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 86. Netherlands Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Spain Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 91. Spain Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 92. Spain Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 93. Spain Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 97. Turkey Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 98. Turkey Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 99. Turkey Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 100. Turkey Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 104. Poland Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 105. Poland Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 106. Poland Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 107. Poland Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 111. South America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 112. South America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 113. South America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 114. South America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 119. Brazil Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 120. Brazil Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 121. Brazil Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 122. Brazil Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 126. Argentina Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 127. Argentina Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 128. Argentina Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 129. Argentina Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 133. Asia-Pacific Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 134. Asia-Pacific Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 135. Asia-Pacific Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 136. Asia-Pacific Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 139. India Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 141. India Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 142. India Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 143. India Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 144. India Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 145. India Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 148. China Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 149. China Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 150. China Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. China Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 152. China Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 155. Japan Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 156. Japan Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 157. Japan Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 158. Japan Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 162. Australia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 163. Australia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 164. Australia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 165. Australia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 169. Vietnam Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 170. Vietnam Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 171. Vietnam Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 172. Vietnam Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 176. South Korea Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 177. South Korea Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 178. South Korea Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 179. South Korea Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. Indonesia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 184. Indonesia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 185. Indonesia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 186. Indonesia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 190. Philippines Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 191. Philippines Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 192. Philippines Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 193. Philippines Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 197. Middle East & Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 198. Middle East & Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 199. Middle East & Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 200. Middle East & Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 205. Saudi Arabia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 206. Saudi Arabia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 207. Saudi Arabia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 208. Saudi Arabia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 212. UAE Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 213. UAE Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 214. UAE Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 215. UAE Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 219. South Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 220. South Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 221. South Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 222. South Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10898

Global cancer biomarkers market size was valued at USD 15.1 billion in 2023, which is expected to reach USD 43.53 billion in 2031, with a CAGR of 14.15% for the forecast period between 2024 and 2031F. The global cancer biomarkers market is expected to grow due to the growing research environment around cancer biomarkers. Cancer biomarkers are a highly effective way of cancer detection as they offer precision diagnostics, since various market players are researching to find more effective and precise cancer biomarkers.

The number of cancer cases has significantly increased in recent years due to factors like genetic mutations, changing lifestyles, smoking, and alcohol consumption. Increasing cancer cases demand more precise and rapid screening methods, which foster market growth. The growing prevalence of cancer patients coupled with cutting-edge technologies is expected to fuel market growth. Factors such as the increasing prevalence of cancer patients, government initiatives, regulatory policies, and technological advancements are expected to fuel market growth.

In July 2023, Quest Diagnostics, the leading provider of diagnostic information services, announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Such cutting-edge product approvals are expected to play a significant role in driving the global cancer biomarkers market.

Increasing Research and Development in Cancer Biomarkers

Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. Cancer biomarkers have been significant contributors to cancer screening. Research institutes and market players are consistently involved in cancer biomarker research which is being supported by government authorities, investors, and regulatory bodies. Research is mainly focused on the identification, optimization, and utilization of different biomarkers to facilitate cancer diagnosis, research, and treatment. Thus, increasing investment by the government in research and development along with companies working in cancer biomarkers space are expected to fuel market growth.

In April 2023, a team led by Florida State University chemists developed a new test for detecting biological markers related to several types of cancer. The sensing platform is made of a gold nanoparticle and molecules called peptides that are labeled with a dye. Chemical bonds connect the components, while the gold nanoparticle restrains the dye from glowing in the presence of UV light. When a patient sample containing Enzyme MMP-14 (a cancer biomarker) is added to the preparation, the peptide bond is broken, separating a fragment with the dye from the gold. Without the gold to absorb the energy from the dye, the sample begins to glow, thus detecting the cancer presence.

Increasing Focus on Protein Biomarker

Protein biomarkers are gaining attention from healthcare professionals as well as patients for cancer screening. The reliability of the protein biomarker as a cancer predictor is of great significance if it is consistently expressed in cancer patients. Furthermore, the protein biomarker's widespread expression can facilitate its identification as a biomarker. Mass spectroscopy-based proteomics tools are utilized for the identification of cancer biomarkers. The increasing focus on protein biomarkers for cancer screening is expected to increase the market demand for protein biomarker-based cancer screenings.

In June 2023, Danish biomarker company Nordic Bioscience announced that its PRO-C3 biomarker assay had received a Letter of Support (LoS) from the United States Food and Drug Administration. PRO C3 is the world's first blood-based tumor fibrosis biomarker based on protein biomarkers for patients with aggressive solid tumors. Regulatory approval of promising products in the global cancer biomarkers market is anticipated to contribute to market growth in forecast years.

Government Initiatives

Government initiatives such as providing research funding, drafting supportive policies, and promoting investments for new establishments are some of the major driving forces for the market. In the global cancer biomarkers market, government organizations, associations, and agencies actively promote cancer screening and treatments through awareness initiatives, thereby fostering the market growth. The governments of several countries are funding research projects addressing cancer diagnostic techniques.

According to a press release from The White House, in March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and Colorectal Cancer Control Program to address the need of screening and treatment of most prevalent type of cancer. In June 2023, as part of the Cancer Moonshot Research Initiatives, the National Institutes of Health, the FNIH, and twelve top pharmaceutical companies announced the start of the five-year, USD 220 million Partnership for Accelerating Cancer Therapies (PACT). PACT is concentrated on finding, creating, and validating strong biomarkers to promote novel treatments and therapies that engage the immune system to combat cancer. The FDA has an advising role in the partnership, which the FNIH manages.

Impact of COVID-19

COVID-19 had a notable impact on the global cancer biomarkers market. During the pandemic COVID-19 patients were of highest priority for healthcare professionals and highlighted the significance of cancer diagnostics and early detection. Cancer biomarkers, which play a pivotal role in the identification of cancer and the monitoring of treatment responses, gained increased attention as healthcare systems worldwide recognized the importance of bolstering cancer care infrastructure. Despite some disruptions in routine cancer screening programs, the pandemic accelerated the adoption of telemedicine and remote monitoring, highlighting the potential for using biomarkers in novel ways. Moreover, the urgent need for more accurate and efficient diagnostic tools spurred research and development efforts in the field of cancer biomarkers. As healthcare systems and hospitals recovered from the pandemic's disruptions, the global cancer biomarkers market saw strong growth, with an increased emphasis on early cancer detection and personalized treatment.

Key Players Landscape and Outlook

Market players are employing a range of strategies to increase their product offerings and give customers access to a wide selection of innovative products. Additionally, companies are expanding the range of diagnostic services offered to capture a bigger portion of the market. Many major industry players are using various growth techniques, like partnerships, mergers and acquisitions, development and launch of new goods, to strengthen their position in the worldwide market.

In September 2023, Ibex launched Galen Breast HER2, an AI-powered solution that helps pathologists for accurate and reproducible biomarker scoring in breast cancer patients. Ibex's Galen Breast HER2 is an AI-powered HER2 receptor scoring system that detects and quantifies the HER2 expression in breast cancer cases and scores it based on 2018 ASCO/CAP scoring guidelines. It can be utilized in screening and checking the effectiveness of treatment being provided to breast cancer patients.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Cancer Biomarkers Market

4. Executive Summary

5. Global Cancer Biomarkers Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Type
    • 5.2.1 Protein Biomarkers
    • 5.2.2 Genetic Biomarkers
      • 5.2.2.1 Breast Cancer Genetic Biomarkers
      • 5.2.2.2 Colorectal Cancer Genetic Biomarkers
      • 5.2.2.3 Leukemia Genetic Biomarkers
      • 5.2.2.4 Lung Cancer Genetic Biomarkers
      • 5.2.2.5 Prostate Cancer Genetic Biomarkers
      • 5.2.2.6 Other Cancer Genetic Biomarkers
    • 5.2.3 Other Cancer Biomarkers
  • 5.3 By Technology
    • 5.3.1 OMICS
      • 5.3.1.1 Proteomics
      • 5.3.1.2 Genomics
      • 5.3.1.2.1 Next Generation Sequencing (NGS)
      • 5.3.1.2.2 Polymerase Chain Reaction (PCR)
      • 5.3.1.2.3 Others
      • 5.3.1.3 Other OMICS Technology
    • 5.3.2 Imaging Technology
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Immunoassays
    • 5.3.4 Bioinformatics
    • 5.3.5 Cytogenetics
      • 5.3.5.1 In-situ Hybridization (ISH)
      • 5.3.5.2 Other Cytogenetics Based Tests
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By Application
    • 5.5.1 Diagnostics
    • 5.5.2 Research and Development
    • 5.5.3 Prognostics
    • 5.5.4 Risk Assessment
    • 5.5.5 Treatment
    • 5.5.6 Other Applications
  • 5.6 By End-user
    • 5.6.1 Pharmaceutical and Biotechnological Companies
    • 5.6.2 Diagnostic Laboratories
    • 5.6.3 Cancer Research Institutes
    • 5.6.4 Others
  • 5.7 By Region
    • 5.7.1 North America
    • 5.7.2 Europe
    • 5.7.3 Asia Pacific
    • 5.7.4 South America
    • 5.7.5 Middle East & Africa
  • 5.8 By Company Market Share (%), 2023

6. Global Cancer Biomarkers Market Outlook, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Type
      • 6.1.2.1. Protein Biomarkers
      • 6.1.2.2. Genetic Biomarkers
      • 6.1.2.2.1. Breast Cancer Genetic Biomarkers
      • 6.1.2.2.2. Colorectal Cancer Genetic Biomarkers
      • 6.1.2.2.3. Leukemia Genetic Biomarkers
      • 6.1.2.2.4. Lung Cancer Genetic Biomarkers
      • 6.1.2.2.5. Prostate Cancer Genetic Biomarkers
      • 6.1.2.2.6. Other Cancer Genetic Biomarkers
      • 6.1.2.3. Other Cancer Biomarkers
    • 6.1.3. By Technology
      • 6.1.3.1. OMICS
      • 6.1.3.1.1. Proteomics
      • 6.1.3.1.2. Genomics
      • 6.1.3.1.2.1. Next Generation Sequencing (NGS)
      • 6.1.3.1.2.2. Polymerase Chain Reaction (PCR)
      • 6.1.3.1.2.3. Others
      • 6.1.3.1.3. Other OMICS Technology
      • 6.1.3.2. Imaging Technology
      • 6.1.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.3.2.2. Computed Tomography (CT)
      • 6.1.3.2.3. Positron Emission Tomography (PET)
      • 6.1.3.2.4. Mammography
      • 6.1.3.2.5. Ultrasound
      • 6.1.3.3. Immunoassays
      • 6.1.3.4. Bioinformatics
      • 6.1.3.5. Cytogenetics
      • 6.1.3.5.1. In-situ Hybridization (ISH)
      • 6.1.3.5.2. Other Cytogenetics Based Tests
    • 6.1.4. By Cancer Type
      • 6.1.4.1. Breast Cancer
      • 6.1.4.2. Lung Cancer
      • 6.1.4.3. Colorectal Cancer
      • 6.1.4.4. Melanoma
      • 6.1.4.5. Blood Cancer
      • 6.1.4.6. Prostate Cancer
      • 6.1.4.7. Ovarian Cancer
      • 6.1.4.8. Stomach Cancer
      • 6.1.4.9. Liver Cancer
      • 6.1.4.10. Other Cancer
    • 6.1.5. By Application
      • 6.1.5.1. Diagnostics
      • 6.1.5.2. Research and Development
      • 6.1.5.3. Prognostics
      • 6.1.5.4. Risk Assessment
      • 6.1.5.5. Treatment
      • 6.1.5.6. Other Applications
    • 6.1.6. By End-user
      • 6.1.6.1. Hospitals
      • 6.1.6.2. Pharmaceutical and Biotechnological Companies
      • 6.1.6.3. Diagnostic Laboratories
      • 6.1.6.4. Cancer Research Institutes
      • 6.1.6.5. Others
    • 6.1.7. United States*
      • 6.1.7.1. Market Size & Forecast
      • 6.1.7.1.1. By Value
      • 6.1.7.1.2. By Volume
      • 6.1.7.2. By Type
      • 6.1.7.2.1. Protein Biomarkers
      • 6.1.7.2.2. Genetic Biomarkers
      • 6.1.7.2.2.1. Breast Cancer Genetic Biomarkers
      • 6.1.7.2.2.2. Colorectal Cancer Genetic Biomarkers
      • 6.1.7.2.2.3. Leukemia Genetic Biomarkers
      • 6.1.7.2.2.4. Lung Cancer Genetic Biomarkers
      • 6.1.7.2.2.5. Prostate Cancer Genetic Biomarkers
      • 6.1.7.2.2.6. Other Cancer Genetic Biomarkers
      • 6.1.7.2.3. Other Cancer Biomarkers
      • 6.1.7.3. By Technology
      • 6.1.7.3.1. OMICS
      • 6.1.7.3.1.1. Proteomics
      • 6.1.7.3.1.2. Genomics
      • 6.1.7.3.1.2.1. Next Generation Sequencing (NGS)
      • 6.1.7.3.1.2.2. Polymerase Chain Reaction (PCR)
      • 6.1.7.3.1.2.3. Others
      • 6.1.7.3.1.3. Other OMICS Technology
      • 6.1.7.3.2. Imaging Technology
      • 6.1.7.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.7.3.2.2. Computed Tomography (CT)
      • 6.1.7.3.2.3. Positron Emission Tomography (PET)
      • 6.1.7.3.2.4. Mammography
      • 6.1.7.3.2.5. Ultrasound
      • 6.1.7.3.3. Immunoassays
      • 6.1.7.3.4. Bioinformatics
      • 6.1.7.3.5. Cytogenetics
      • 6.1.7.3.5.1. In-situ Hybridization (ISH)
      • 6.1.7.3.5.2. Other Cytogenetics Based Tests
      • 6.1.7.4. By Cancer Type
      • 6.1.7.4.1. Breast Cancer
      • 6.1.7.4.2. Lung Cancer
      • 6.1.7.4.3. Colorectal Cancer
      • 6.1.7.4.4. Melanoma
      • 6.1.7.4.5. Blood Cancer
      • 6.1.7.4.6. Prostate Cancer
      • 6.1.7.4.7. Ovarian Cancer
      • 6.1.7.4.8. Stomach Cancer
      • 6.1.7.4.9. Liver Cancer
      • 6.1.7.4.10. Other Cancer
      • 6.1.7.5. By Application
      • 6.1.7.5.1. Diagnostics
      • 6.1.7.5.2. Research and Development
      • 6.1.7.5.3. Prognostics
      • 6.1.7.5.4. Risk Assessment
      • 6.1.7.5.5. Treatment
      • 6.1.7.5.6. Other Applications
      • 6.1.7.6. By End-user
      • 6.1.7.7. Hospitals
      • 6.1.7.8. Pharmaceutical and Biotechnological Companies
      • 6.1.7.9. Diagnostic Laboratories
      • 6.1.7.10. Cancer Research Institutes
      • 6.1.7.11. Others
    • 6.1.8. Canada
    • 6.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Type
  • 7.2. By Technology
  • 7.3. By Cancer Type
  • 7.4. By Application
  • 7.5. By End-user
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Abbott
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Illumina, Inc.
  • 14.4. QIAGEN
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Quest Diagnostics Incorporated
  • 14.8. Merck KGaA
  • 14.9. Hologic, Inc.
  • 14.10. Bio-Rad Laboratories

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer